People alive many years after breast (BC) or colorectal cancer (CRC) diagnoses are increasing. This paper aimed to estimate the indicators of cancer cure and complete prevalence for Italian patients with BC and CRC by stage and age. A total of 31 Italian Cancer Registries (47% of the population) data until 2017 were included. Mixture cure models allowed estimation of net survival (NS); cure fraction (CF); time to cure (TTC, 5-year conditional NS >95%); cure prevalence (who will not die of cancer); and already cured (prevalent patients living longer than TTC). 2.6% of all Italian women (806,410) were alive in 2018 after BC and 88% will not die of BC. For those diagnosed in 2010, CF was 73%, 99% when diagnosed at stage I, 81% at stage II, and 36% at stages III–IV. For all stages combined, TTC was >10 years under 45 and over 65 years and for women with advanced stages, but ≤1 year for all BC patients at stage I. The proportion of already cured prevalent BC women was 75% (94% at stage I). Prevalent CRC cases were 422,407 (0.7% of the Italian population), 90% will not die of CRC. For CRC patients, CF was 56%, 92% at stage I, 71% at stage II, and 35% at stages III–IV. TTC was ≤10 years for all age groups and stages. Already cured were 59% of all prevalent CRC patients (93% at stage I). Cancer cure indicators by stage may contribute to appropriate follow-up in the years after diagnosis, thus avoiding patients' discrimination.

中文翻译：

---

乳腺癌和结直肠癌患者诊断时各阶段的治愈指标和患病率：意大利的一项基于人群的研究

乳腺癌 (BC) 或结直肠癌 (CRC) 诊断后存活多年的人数正在增加。本文旨在按阶段和年龄评估意大利 BC 和 CRC 患者的癌症治愈率和完全患病率指标。截至 2017 年，总共包括 31 个意大利癌症登记处（占人口的 47%）数据。混合固化模型可以估计净存活率 (NS)；固化分数（CF）；治愈时间（TTC，5 年有条件 NS >95%）；治愈率（谁不会死于癌症）；并且已经治愈（普遍患者的寿命比 TTC 长）。 2018 年，2.6% 的意大利女性 (806,410) 在 BC 后仍存活，88% 不会死于 BC。对于2010年诊断的患者，CF为73%，在I期诊断时为99%，在II期诊断时为81%，在III-IV期诊断时为36​​%。对于所有分期合计，45 岁以下和 65 岁以上以及晚期女性的 TTC >10 年，但所有 I 期 BC 患者的 TTC ≤ 1 年。已治愈的流行 BC 女性比例为 75%（94%阶段I）。 CRC流行病例为422,407例（占意大利人口的0.7%），90%不会死于CRC。对于 CRC 患者，CF 为 56%，I 期为 92%，II 期为 71%，III-IV 期为 35%。所有年龄组和阶段的 TTC ≤ 10 年。所有流行的 CRC 患者中 59% 已经治愈（93% 处于 I 期）。分阶段的癌症治愈指标可能有助于诊断后数年的适当随访，从而避免患者受到歧视。